Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open‐label study
Lijuan Deng(Peking University), Jun Zhu(Peking University), Huilai Zhang(Shanxi Medical University), Zhiming Li(Anhui Medical University), Yue-Rong Shuang(Jiangxi Provincial Cancer Hospital), Zimin Sun(University of Science and Technology of China), Shuhua Yi(Chinese Academy of Medical Sciences & Peking Union Medical College), Chunyan Ji(Nanjing University of Chinese Medicine), Zunmin Zhu(Zhengzhou University), Haiyan Yang(Zhejiang Cancer Hospital), Keshu Zhou(Zhengzhou University), Haiwen Huang(Second Affiliated Hospital of Soochow University), Renbin Zhao(Kunming University of Science and Technology), Yu Hu(Wuhan Union Hospital), Jianda Hu(Fujian Medical University), Junning Cao(Fudan University Shanghai Cancer Center), Dengju Li(Tongji Hospital), Sujun Gao(Jilin University), Mingzhi Zhang(Chinese Academy of Sciences), Wenyu Li(Shenyang Agricultural University), Ting Liu(Chinese PLA General Hospital), Lihong Liu(Hebei Medical University), Yue Du, Qingyuan Zhang(Third Affiliated Hospital of Harbin Medical University), Jie Jin(First Affiliated Hospital Zhejiang University), Cheng Hou, Liansheng Zhang(Chinese Academy of Sciences), Yuqin Song(Peking University), Wenrong Huang(Chinese PLA General Hospital), Weige Wang(Shanghai Medical College of Fudan University), Hui Zhou(Hunan Cancer Hospital), Zhenqian Huang(First Affiliated Hospital of Guangzhou Medical University), Kaiyang Ding(Anhui Provincial Hospital)
Cited by 18
Related Papers
Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
|Science Immunology|2020|555
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia
|EBioMedicine|2016|345
Association analyses identify six new psoriasis susceptibility loci in the Chinese population
|Nature Genetics|2010|317
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296